Partner with BluePrint Orphan: Strategic Advisory Services
As the Orphan industry's preeminent leader in licensing strategy and opportunity identification & assessment, BluePrint Orphan is the optimal corporate partner for streamlining successful deals and meaningfully enhancing ROI and DCF results. Whether exploring gene therapies, vector platform-opportunities, the most ultra rare diseases in the world, or therapies that will face multiple targeted competitors at launch, the right strategic approach will differentiate companies that dramatically transform patients' lives from those that face perpetual challenges securing regulatory approval, access, and market share.
Deal opportunity sourcing: Active relationships with hundreds of companies developing Orphan products. Meticulous monitoring of clinical and pre-clinical pipeline developments, as well as academic IP.
Portfolio strategy fit: Identification of synergies including sales force/MSL deployment, global commercialization/development capabilities and associated partnerships.
Patient forecasting: Global sizing of rare disease patient populations, including currently undiagnosed populations which can be highly significant in Orphan disease.
Pricing & access: Country-level pricing & access modeling based on decades of experience, analogs, and close relationships with private and government decision-makers.
Deal valuation & structuring: triangulation of valuation methods to arrive optimal offer magnitudes and milestone structures.
Introductions & coordination: Direct relationships with hundreds of large and small biopharma companies, as well as international reach and language capabilities allow for efficient coordination of meetings and communication between parties.
Portfolio strategy fit: Identification of synergies including sales force/MSL deployment, global commercialization/development capabilities and associated partnerships.
Patient forecasting: Global sizing of rare disease patient populations, including currently undiagnosed populations which can be highly significant in Orphan disease.
Pricing & access: Country-level pricing & access modeling based on decades of experience, analogs, and close relationships with private and government decision-makers.
Deal valuation & structuring: triangulation of valuation methods to arrive optimal offer magnitudes and milestone structures.
Introductions & coordination: Direct relationships with hundreds of large and small biopharma companies, as well as international reach and language capabilities allow for efficient coordination of meetings and communication between parties.
Top 3 reasons clients choose BluePrint Orphan vs. other investment banks or consultancies:
- We are experts in Orphan. (with a history of having launched some of the world's most prominent brands)
- Senior-heavy team with vast, global experience across therapeutic areas.
- Modest, success-based fees. We succeed when our clients do.